Clinical features, diagnostic criteria and pathogenesis of diabetes mellitus

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 340-355

  Imam, Khalid ^a  

^a CIVIL HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DIABETOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON COMMUNICABLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANDEMIC; PATHOPHYSIOLOGY; VASCULAR DISEASE; ENDOCRINE SYSTEM EXAMINATION; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC TECHNIQUES, ENDOCRINE; HUMANS;

MLCS; MLOWN;

EID: 84874551621     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_25     Document Type: Article

References (63)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
2. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362:1090-101.
3. Fox CS, Pencina MJ, Meigs JB, et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006; 113:2914-8.
4. International Diabetes Foundation. IDF Diabetes Atlas, 4th ed. Brussels: International Diabetes Foundation, 2009.
5. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140:945.
6. Dabelea D, Pettitt DJ, Hanson RL, et al. Birth weight, type 2 diabetes and insulin resistance in Pima Indian children and young adults. Diabetes Care 1999; 22:944-50.
7. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.
8. Daneman D. Type 1 diabetes. Lancet 2006; 367:847-58.
9. Classification and diagnosis of Diabetes: Clinical practice recommendation. Diabetes Care 2011; 26 (Suppl 1):S11-3.
10. Eisenbarth GS. Classification, diagnostic tests and Pathogenesis. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincot Williams and Wilkins, 2001:1315-1319.
11. Umesh M. Diabetes mellitus and hypoglycemia. In: McPhee SJ, Papadakis M, eds. Current Medical Diagnosis and Treatment. USA: McGraw-Hill, 2010:1079-1121.
12. Nathan DM, Singer DE, Hurxthal K. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341-6.
13. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C Assay into estimated average glucose values. Diabetes Care 2008; 31:1473.
14. Panzer S, Kronik G, Lechner K, et al. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59:1348-50.
15. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003; 37:e53.
16. Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A1C in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29:468-72.
17. Narbonne H, Renacco E, Pradel V, et al. Can fructosamine be a surrogate for HbA(1c) in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 2001; 27:598-603.
18. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428.
19. Vehik K, Hamman RF, Lezotte D, et al. Increasing incidence of type 1 diabetes in 0-to 17-year-old Colorado youth. Diabetes Care 2007; 30:503-9.
20. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51:3353-61.
21. Todd J A, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857-64.
22. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (S1c30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104:17040-5.
23. Niskanen LK, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18:1557-65.
24. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia and auto antibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52:2623-9.
25. Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999;318:698-702.
26. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94:1714.
27. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140:945-50.
28. Houmard JA, Weidner MD, Dolan PL. Skeletal muscle GLUT4 protein concentration and aging in humans. Diabetes 1995; 44:555-60.
29. Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1995; 92:983.
30. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.
31. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92:399-404.
32. Milner KL, Van Der Poorten D, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138:932-41.
33. De Fronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88:787-835.
34. Chen M, Bergman RN, Pacini G, et al. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985; 60:13-20.
35. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40(Suppl):S21-5.
36. Leahy JL, Irl BH, Kevin AP, et al. Targeting β-cell function early in the course of therapy for type2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:4206-16.
37. Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992; 13:415-31.
38. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 1994; 43:1085-9.
39. Olefsky J, Farquhar JW, Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 1973; 22:507-13.
40. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42:1663-72.
41. De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15:318-68.
42. Klöppel G, Lohr M, Habich K, et al. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4:110-25.
43. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits beta cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80:1584-90.
44. Chia CW. Chia, Josephine M. Egan incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008; 93:3703-16.
45. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63:492-8.
46. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86:3717-23.
47. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-58.
48. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology 2004; 145:2653-9.
49. Egan JM, Bulotta A, Hui H, et al. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet cells. Diabetes Metab Res Rev 2003; 19:115-23.
50. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86:4382-9.
51. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96:1261.
52. Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest 2007; 117:2753-6.
53. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116:1784-92.
54. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006; 354:2552-63.
55. Gat-Yablonski G, Shalitin S, Phillip M. Maturity onset diabetes of the young. Pediatr Endocrinol Rev 2006;3(Suppl 3):514-20.
56. Holmkvist J, Almgren P, Lyssenko V, et al. Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 2008; 57:1738-44.
57. Neel JV. "Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962; 14:353-62.
58. Forsén T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176-82.
59. Ritenbaugh C, Goodby CS. Beyond the thrifty gene: metabolic implications of prehistoric migration into the New World. Med Anthropol 1989; 11:227-226.
60. Zander M, Madsbad S, Madsen JL. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-30.
61. Westermark P, Johnson KH, O'Brien TD. Islet amyloid polypeptide-a novel controversy in diabetes research. Diabetologia 1992; 35:297.
62. Mathieu C, Gysemans C, Giulietti A, et al. Vitamin D and diabetes. Diabetologia 2005; 48:1247-57.
63. Bin-Abbas BS, Jabari MA, Issa SD, et al. Vitamin D levels in Saudi Children with type 1 diabetes. Saudi Med J 2011; 32:589-92.